References
- Heesen C, Böhm J, Reich C, et al. Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable. Mult Scler 2008;14:988-91
- Salter AR, Cutter GR, Tyry T, et al. Impact of loss of mobility on instrumental activities of daily living and socioeconomic status in patients with MS. Curr Med Res Opin 2010;26:493-500
- Albrecht H, Wotzel C, Erasmus LP, et al. Day-to-day variability of maximum walking distance in MS patients can mislead to relevant changes in the Expanded Disability Status Scale (EDSS): average walking speed is a more constant parameter. Mult Scler 2001;7:105-9
- Schwid S, Goodman AD, Mattson DH, et al. The measurement of ambulatory impairment in multiple sclerosis. Neurology 1997;49:1419-24
- Bethoux F, Bennett S. Evaluating walking in patients with multiple sclerosis: which assessment tools are useful in clinical practice? Int J MS Care 2011;13:4-14
- Guyatt GH, Osaba D, Wu AW, et al. for the Clinical Significance Consensus Meeting Group: methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002;77:371-83
- Kaufman M, Moyer D, Norton J. The significant change for the timed 25-foot walk in the Multiple Sclerosis Functional Composite. Mult Scler 2000;6:286-90
- Schwid SR, Goodman AD, McDermott MP, et al. Quantitative functional measures in MS: what is a reliable change? Neurology 2002;58:1294-6
- Hoogervorst EL, Kalkers NF, Cutter GR, et al. The patient’s perception of a (reliable) change in the Multiple Sclerosis Functional Composite. Mult Scler 2004;10:55-60
- Kragt JJ, van der Linden FAH, Nielsen JM, et al. Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis. Mult Scler 2006;12:594-8
- van Winsen LM, Kragt JJ, Hoogervorst EL, et al. Outcome measurement in multiple sclerosis: detection of clinically relevant improvement. Mult Scler 2010;16:604-10
- Goodman AD, Brown TR, Krupp LB, et al. Fampridine MS-F203 Investigators. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009;373:732-8
- Revicki D, Hays RD, Cella D, et al. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 2008;61:102-9
- Cohen JA, Fischer JS, Bolibrush DM, et al. Intrarater and interrater reliability of the MS Functional Composite outcome measure. Neurology 2000;54:802-6
- Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd edn. Hillsdale, NJ, USA: Lawrence Erlbaum Associates, 1988
- Wyrwich KW, Tierney W, Wolinsky F. Further evidence supporting an SEM-based criteria for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 1999;52:861-73
- Weir JP. Quantifying test–retest reliability using the intraclass correlation coefficient and the SEM. J Strength Cond Res 2005;19:231-40
- Abetz L, Arbuckle R, Allen RP, et al. The reliability, validity and responsiveness of the Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) in a trial population. Health Qual Life Outcomes 2005;3:79
- Cella D, Hahn EA, Dineen K. Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res 2002;11:207-21
- Gilbert C, Brown MC, Cappelleri JC, et al. Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. Chest 2009;135:137-42